特应性皮炎的全身治疗：欢迎变革。

Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution.

作者信息

Eichenfield Lawrence F, Stein Gold Linda F

机构信息

Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology Chief, Pediatric and Adolescent Dermatology University of California San Diego School of Medicine and Rady Children's Hospital-San Diego University of California San Diego, California.

Director of Dermatology Research Henry Ford Health System Detroit, Michigan.

出版信息

Semin Cutan Med Surg. 2017 Dec 1;36(4S):S103-S105. doi: 10.12788/j.sder.2017.051.

DOI:10.12788/j.sder.2017.051

PMID:29659645

Abstract

Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and "small molecules" with varying mechanisms of action are in phase 2 or 3 development. Semin Cutan Med Surg 36(supp4):S103-S105.

摘要

直到最近，特应性皮炎的全身治疗还局限于免疫调节剂的非标签使用（这可能带来重大安全问题）以及全身用皮质类固醇治疗（最新指南不推荐使用）。2017年度普利尤单抗的推出标志着特应性皮炎全身治疗取得了重大进展。它已在中重度疾病的成人患者中显示出长期疗效，并且正在儿童患者中进行研究。其他几种作用机制各异的生物制剂和“小分子”正处于2期或3期研发阶段。《皮肤外科学与医学杂志》36（增刊4）：S103 - S105。